Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20153502 | 1.00 | ACHE (0.44) | ACHEPOLBBLMSIGMAR1MAOB | |
| SCHEMBL17865775 | 1.00 | ACHE (0.44) | ACHEPOLBBLMSIGMAR1MAOB | |
| SCHEMBL17865732 | 0.87 | POLB (0.46) | POLBALDH1A1USP2LMNAKMT2A | |
| SCHEMBL20153496 | 0.87 | POLB (0.46) | POLBALDH1A1USP2LMNAKMT2A | |
| SCHEMBL17865733 | 0.87 | POLB (0.46) | POLBALDH1A1USP2LMNAKMT2A | |
| SCHEMBL19521228 | 0.82 | ADAMTS5 (0.48) | — | |
| SCHEMBL19521230 | 0.82 | ADAMTS5 (0.48) | — | |
| SCHEMBL19521240 | 0.82 | ADAMTS5 (0.48) | — | |
| SCHEMBL19541331 | 0.82 | ADAMTS5 (0.48) | — | |
| SCHEMBL17999632 | 0.81 | PIK3CD (0.35) | ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057808-A1 | COMPOSITION COMPRISING BETA LACTAM FOR TREATING ALCOHOL DEPENDENCE AND ALCOHOL ASSOCIATED DISEASES OR CONDITIONS | UNIVERSITY OF TOLEDO | 2025-02-20 | — | — | US | claimed |
| US-9975879-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-22 | — | — | US | claimed |
| WO-2016184911-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF THE NEUROPATHOLOGY OF PATIENTS SUFFERING FROM MYOTONIC DYSTROPHY TYPE 1 (DM1) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-11-24 | — | — | WO | claimed |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-11 | — | — | US | claimed |
| EP-3036219-A2 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | Temple University Of The Commonwealth System Of Higher Education (US) | 2016-06-29 | — | — | EP | claimed |
| US-20250057808-A1 | COMPOSITION COMPRISING BETA LACTAM FOR TREATING ALCOHOL DEPENDENCE AND ALCOHOL ASSOCIATED DISEASES OR CONDITIONS | UNIVERSITY OF TOLEDO | 2025-02-20 | — | — | US | disclosed |
| US-9975879-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975879-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975879-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-22 | — | — | US | disclosed |
| WO-2016184911-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF THE NEUROPATHOLOGY OF PATIENTS SUFFERING FROM MYOTONIC DYSTROPHY TYPE 1 (DM1) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-11-24 | — | — | WO | disclosed |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-11 | — | — | US | disclosed |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-11 | — | — | US | disclosed |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-11 | — | — | US | disclosed |
| EP-3036219-A2 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | Temple University Of The Commonwealth System Of Higher Education (US) | 2016-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057808-A1 | COMPOSITION COMPRISING BETA LACTAM FOR TREATING ALCOHOL DEPENDENCE AND ALCOHOL ASSOCIATED DISEASES OR CONDITIONS | ADH1A, ADH1C, SLC10A1 | ACHE 497/4885POLB 2432/4885BLM 4085/4885 |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | SLC1A2, SLC7A11, SLC18A2 | ACHE 285/4885POLB 1829/4885BLM 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.